65
Participants
Start Date
February 13, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Cofetuzumab Pelidotin
Intravenous (IV) infusion
Linkou Chang Gung Memorial Hospital /ID# 222603, Taoyuan
National Cheng Kung University Hospital /ID# 222602, Tainan City
CHA Bundang Medical Center /ID# 232514, Seongnam
Virginia Cancer Specialists - Fairfax /ID# 216427, Fairfax
Hospital Universitario Fundacion Jimenez Diaz /ID# 215110, Madrid
Hospital Universitario HM Sanchinarro /ID# 215102, Madrid
University of Alabama at Birmingham - Main /ID# 213605, Birmingham
Tennessee Oncology, PLLC /ID# 215326, Nashville
Washington University-School of Medicine /ID# 213453, St Louis
Highlands Oncology Group, PA /ID# 215383, Springdale
University of Texas MD Anderson Cancer Center /ID# 215876, Houston
Univ of Colorado Cancer Center /ID# 215295, Aurora
Rambam Health Care Campus /ID# 217536, Haifa
Rabin Medical Center /ID# 217537, Petah Tikva
The Chaim Sheba Medical Center /ID# 217538, Ramat Gan
Duplicate_Stanford University School of Med /ID# 213450, Stanford
Sylvester Comprehensive Cancer Center /ID# 216433, Miami
Moffitt Cancer Center /ID# 215101, Tampa
The Ohio State University /ID# 211088, Columbus
Oncology Consultants /ID# 215932, Houston
National Cancer Center Hospital East /ID# 218537, Kashiwa-shi
National Cancer Center Hospital /ID# 218536, Chuo-ku
Asan Medical Center /ID# 222280, Seoul
Samsung Medical Center /ID# 222906, Seoul
Yonsei University Health System Severance Hospital /ID# 222281, Seoul
Hospital Universitario Vall d'Hebron /ID# 215729, Barcelona